GUTS logo

FRACTYL HEALTH INC

GUTSNASDAQ
🏆 #4787 by market capEarnings Nov 11US Equity
$0.88▲ $0.02 (+2.78%)
Pre-market · at close
🔔
Track GUTS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.8%
7d▼ 22.7%
14d▼ 78.6%
30d▼ 85.8%
ytd▼ 96.7%
1y▼ 94.1%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
46.2%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
152.6x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.86 – $0.90
52-Week Range
$1.02 – $29.34
Volume (shares)
4,669
Avg Volume (shares)
—
Shares Outstanding
13.3M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
152.6x
EPS (TTM)
$-2.07
Dividend Yield
—
Dilution (1yr)
+214.6%
GUTS logo

FRACTYL HEALTH INC

GUTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
46.2%▲ +29.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$97M▲ +3.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$91M▲ +35.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.8M▲ +214.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▲ +$15M YoY
StockOtter · stockotter.space

About FRACTYL HEALTH INC

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
13 analysts
Strong Buy4
Buy7
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.